MoonLake Competitors
MLTX Stock | USD 40.66 0.38 0.93% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of MoonLake Immunotherapeuti competition on your existing holdings.
MoonLake |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of MoonLake Immunotherapeuti's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
MoonLake Immunotherapeuti Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between MoonLake Immunotherapeuti and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of MoonLake and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of MoonLake Immunotherapeuti does not affect the price movement of the other competitor.
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between MoonLake Stock performing well and MoonLake Immunotherapeuti Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze MoonLake Immunotherapeuti's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
TERN | 3.95 | (0.23) | 0.00 | (0.33) | 0.00 | 7.30 | 27.76 | |||
DAWN | 3.24 | (0.32) | 0.00 | (0.22) | 0.00 | 6.30 | 21.23 | |||
ABOS | 3.04 | (0.56) | 0.00 | (0.15) | 0.00 | 7.08 | 19.42 | |||
AMLX | 4.38 | (2.33) | 0.00 | (0.75) | 0.00 | 5.88 | 84.59 | |||
AVTE | 4.02 | (0.38) | 0.00 | (0.14) | 0.00 | 8.97 | 25.68 | |||
ELVN | 4.82 | 0.55 | 0.13 | 0.21 | 4.36 | 9.52 | 50.27 | |||
GPCR | 2.58 | (0.32) | 0.00 | (0.51) | 0.00 | 5.89 | 20.91 | |||
CMPX | 3.34 | (0.31) | 0.00 | (0.10) | 0.00 | 6.74 | 25.52 | |||
VTYX | 4.59 | (0.57) | 0.00 | (0.32) | 0.00 | 17.39 | 39.01 |
Cross Equities Net Income Analysis
Compare MoonLake Immunotherapeuti and related stocks such as Terns Pharmaceuticals, Day One Biopharmaceu, and Acumen Pharmaceuticals Net Income Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.8 M) | (40.6 M) | (50.2 M) | (60.3 M) | (90.2 M) | (85.7 M) |
DAWN | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (179.5 M) |
ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (181.7 M) | (40.5 M) | (52.4 M) | (55 M) |
AVTE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (9 M) | (23 M) | (51.5 M) | (75.5 M) | (71.7 M) |
ELVN | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (23.5 M) | (18.9 M) | (24.7 M) | (37.8 M) | (71.6 M) | (68 M) |
GPCR | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (38 K) | (51.3 M) | (89.5 M) | (85.1 M) |
CMPX | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (34.7 M) | (29.5 M) | (82.6 M) | (36.8 M) | (42.5 M) | (44.6 M) |
VTYX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (28.5 M) | (78.4 M) | (108 M) | (193 M) | (183.3 M) |
NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.3 M) | (73.3 M) | (126.2 M) | (119.9 M) |
CERE | (29.4 M) | (29.4 M) | (29.4 M) | (32.5 M) | (29.3 M) | (28.2 M) | (463.6 K) | (463.6 K) | (463.6 K) | (128.4 M) | (152.1 M) | (222.4 M) | (351.5 M) | (432.8 M) | (411.2 M) |
TVTX | (18.3 K) | (14.8 K) | (30.3 M) | (33.8 M) | (110.9 M) | 117.2 M | (47.9 M) | (59.7 M) | (102.7 M) | (146.4 M) | (169.4 M) | (180.1 M) | (278.5 M) | (111.4 M) | (117 M) |
ACLX | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (32.1 M) | (63.9 M) | (186.1 M) | (70.7 M) | (74.2 M) |
AKRO | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (81.7 M) | (43.8 M) | (79.2 M) | (100.7 M) | (108.9 M) | (151.8 M) | (144.2 M) |
ETNB | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (57.4 M) | (49.5 M) | (90.1 M) | (102 M) | (142.2 M) | (135.1 M) |
PLRX | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | 185 K | (39.7 M) | (17.9 M) | (121.5 M) | (161.3 M) | (153.3 M) |
MoonLake Immunotherapeuti and related stocks such as Terns Pharmaceuticals, Day One Biopharmaceu, and Acumen Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in MoonLake Immunotherapeuti financial statement analysis. It represents the amount of money remaining after all of MoonLake Immunotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.MoonLake Immunotherapeuti Competitive Analysis
The better you understand MoonLake Immunotherapeuti competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, MoonLake Immunotherapeuti's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across MoonLake Immunotherapeuti's competition over several years is one of the best ways to analyze its investment potential.Better Than Average | Worse Than Peers | View Performance Chart |
MoonLake Immunotherapeuti Competition Performance Charts
Five steps to successful analysis of MoonLake Immunotherapeuti Competition
MoonLake Immunotherapeuti's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by MoonLake Immunotherapeuti in relation to its competition. MoonLake Immunotherapeuti's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of MoonLake Immunotherapeuti in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact MoonLake Immunotherapeuti's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to MoonLake Immunotherapeuti, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your MoonLake Immunotherapeuti position
In addition to having MoonLake Immunotherapeuti in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Gainers Thematic Idea Now
Latest Gainers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 144 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Gainers Theme or any other thematic opportunities.
View All Next | Launch |
Check out MoonLake Immunotherapeuti Correlation with its peers. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for MoonLake Stock analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is MoonLake Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MoonLake Immunotherapeuti. If investors know MoonLake will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MoonLake Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.72) | Return On Assets (0.12) | Return On Equity (0.15) |
The market value of MoonLake Immunotherapeuti is measured differently than its book value, which is the value of MoonLake that is recorded on the company's balance sheet. Investors also form their own opinion of MoonLake Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is MoonLake Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MoonLake Immunotherapeuti's market value can be influenced by many factors that don't directly affect MoonLake Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MoonLake Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if MoonLake Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MoonLake Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.